CSL Limited (CSL.AX) Stock Analysis & Winston Score

CSL Limited is an Australian biotechnology company that collects human blood plasma and turns it into life-saving medicines. Its main products treat rare diseases like immune deficiencies, bleeding disorders such as hemophilia, and neurological conditions. CSL also makes flu vaccines through its Seqirus division, making it one of the largest influenza vaccine producers in the world. CSL earns money by selling these plasma-derived therapies and vaccines to hospitals, clinics, and governments across more than 100 countries. Most revenue comes from the United States, Europe, and Australia, and the company generates roughly $14 billion in annual revenue. Its moat comes from the expensive, complex process of collecting and fractionating plasma, which takes years to scale and is difficult for competitors to replicate. The key growth driver is expanding its plasma collection network and ramping up sales of Garadacimab, a newly approved treatment for hereditary angioedema, though rising collection costs remain a pressure on margins.